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Abstract
 
Manganese superoxide dismutase 2 (SOD2) is a critical component of the mitochondrial path-
 
way for detoxification of O
 
2
 
2
 
, and targeted disruption of this locus leads to embryonic or neo-
natal lethality in mice. To follow the effects of SOD2 deficiency in cells over a longer time
course, we created hematopoietic chimeras in which all blood cells are derived from fetal liver
stem cells of 
 
Sod2
 
 knockout, heterozygous, or wild-type littermates. Stem cells of each geno-
type efficiently rescued hematopoiesis and allowed long-term survival of lethally irradiated host
animals. Peripheral blood analysis of leukocyte populations revealed no differences in reconsti-
tution kinetics of T cells, B cells, or myeloid cells when comparing 
 
Sod2
 
1
 
/
 
1
 
, 
 
Sod2
 
2
 
/
 
2
 
, and
 
Sod2
 
1
 
/
 
2 
 
fetal liver recipients. However, animals receiving 
 
Sod2
 
2
 
/
 
2
 
 cells were persistently ane-
mic, with findings suggestive of a hemolytic process. Loss of SOD2 in erythroid progenitor
cells results in enhanced protein oxidative damage, altered membrane deformation, and re-
duced survival of red cells. Treatment of anemic animals with Euk-8, a catalytic antioxidant
with both SOD and catalase activities, significantly corrected this oxidative stress–induced con-
dition. Such therapy may prove useful in treatment of human disorders such as sideroblastic
anemia, which SOD2 deficiency most closely resembles.
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Introduction
 
Manganese superoxide dismutase 2 (SOD2)
 
1
 
 is a nuclear-
encoded mitochondrial protein that converts superoxide
radicals to H
 
2
 
O
 
2
 
, which is then acted upon by glutathione
peroxidase or catalase to yield nontoxic products (1). Simi-
lar enzymes have been isolated from the cytoplasm (SOD1
or CuZnSOD) and extracellular fluids (SOD3; reference
2). Together, these enzyme systems are responsible for
protecting cells from reactive oxygen species (ROS) gen-
erated from endogenous and exogenous sources. Endoge-
nous ROS produced by mitochondria as a by-product of
respiration are proposed to be a major causal factor in or-
ganismal aging and cellular senescence. Support for this
hypothesis comes from studies of model organisms in
which increased longevity has been correlated with the en-
hanced ability to withstand oxidative stress (3–5), or with
decreased endogenous production of ROS (6, 7). Con-
versely, impairment of an organism’s ability to withstand
oxidative stress, or increased generation of endogenous
ROS, leads to a shortened life span characterized by accel-
erated aging phenotypes (8, 9). The relevance of oxidative
stress as a determinant of mammalian longevity is sup-
ported by a recent study demonstrating that an oxidative
stress–activated signal transduction pathway is linked to ap-
optosis and regulates life span in mice (10). The possibility
of altering longevity through pharmacological intervention
to ameliorate ROS-induced damage has also been ex-
 
plored in a recent study in which 
 
Caenorhabiditis elegans
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Abbreviations used in this paper:
 
 CBC, complete blood count; MCV,
mean corpuscular volume; ROS, reactive oxygen species; SA, sidero-
blastic anemia; SOD, superoxide dismutase. 
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were treated with a novel class of antioxidants placed di-
rectly into the growth medium, resulting in extension of
mean life span by 
 
.
 
40% (11).
 
Sod2
 
 knockout mice were originally produced indepen-
dently on two separate strain backgrounds (12, 13), both of
which demonstrate a lethal phenotype in which the time of
death is dependent on the genetic background. 
 
Sod2
 
2
 
/
 
2
 
animals have pathologic evidence of mitochondrial injury,
with corresponding evidence of damage to cardiac muscle
and neural tissues as well as metabolic derangement includ-
ing acidosis and lipid accumulation. A partial rescue of this
phenotype has been reported by using the synthetic SOD
mimetic manganese 5, 10, 15, 20-tetrakis(4-benzoic acid)
porphorin (MnTBAP), although treated animals succumb
to neural degeneration within several weeks of birth, pre-
sumably because of failure of this agent to cross the blood–
brain barrier (14). In addition to early lethality, 
 
Sod2
 
2
 
/
 
2
 
animals have increased oxidative DNA damage and respira-
tory chain defects in mitochondria (15). Heterozygous ani-
mals appear normal, but also show oxidative damage to mi-
tochondrial DNA, decreased levels of reduced glutathione,
and altered mitochondrial function (16, 17). Thus, 
 
Sod2
 
-
deficient mice demonstrate evidence of increased damage
from mitochondrial ROS, but
 
 
 
because of the severe and
pleiotropic nature of the defect in 
 
Sod2
 
2
 
/
 
2
 
 animals, it has
not been possible to study the effects of SOD2 deficiency
in cells over long periods of time in vivo.
To circumvent this problem, we constructed a transplant
system in which 
 
Sod2
 
2
 
/
 
2
 
 cells replace host hematopoietic
cells and can be maintained for several months in vivo.
This system places 
 
Sod2
 
-deficient cells in a metabolically
normal host animal, allowing for the assessment of cell au-
tonomous phenotypes caused by increased intracellular
damage from mitochondrial ROS. This makes possible an
assessment of the specific role of mitochondrial antioxidant
protective systems on immune and hematopoietic cell re-
constitution and function. We report that murine fetal liver
stem cells deficient in 
 
Sod2
 
 are capable of efficiently rescu-
ing lethally irradiated host animals. However, whereas lym-
phoid and myeloid engraftment kinetics and durability are
identical across all 
 
Sod2
 
 fetal liver genotypes (
 
1
 
/
 
1
 
, 
 
2
 
/
 
2
 
,
and 
 
1
 
/
 
2
 
) there is a selective defect in erythroid reconsti-
tution of 
 
Sod2
 
2
 
/
 
2
 
 fetal liver recipients. This defect is similar
to that seen clinically in hereditary and acquired sideroblas-
tic anemias (SAs), which are believed to involve abnormal
oxidation of red cell proteins and which may be caused by
defects in mitochondria (18, 19).
 
Materials and Methods
 
Generation of Donor Cells for Fetal Liver Transplantation.
 
Het-
erozygous B6-
 
Sod2
 
tm1Cje
 
 mice (12) were bred in timed matings in
order to obtain 
 
Sod2
 
2
 
/
 
2
 
, 
 
Sod2
 
1
 
/
 
2
 
, and 
 
Sod2
 
1
 
/
 
1
 
 littermates at
E13.5-16.5 of development to serve as donors for fetal liver cell
transplantation. Animals (two females, one male) were placed to-
gether for two or three consecutive nights, after which time
males were removed. Pregnant females were killed on the 17th
morning after the introduction of the male. Embryos were har-
 
vested, and fetal livers were dissected. All fetal livers were me-
chanically dissociated into a single cell suspension by pipetting up
and down using an Eppendorf p-1000 pipette in 1 cc of culture
medium (RPMI, 7% FCS, glutamine, penicillin-streptomycin,
and 10
 
2
 
5 
 
M betamercapto-ethanol). 5% of each sample was used
for DNA extraction followed by PCR analysis for genotyping.
Knockout (
 
Sod2
 
2
 
/
 
2
 
) fetuses were often more pale than 
 
1
 
/
 
2
 
 or
 
1
 
/
 
1
 
 littermates at the time of harvest, but were otherwise indis-
tinguishable. At E13.5-16.5, 15% of genotyped animals were
 
Sod2
 
2
 
/
 
2
 
, consistent with a previous report of decreased frequency
of 
 
Sod2
 
2
 
/
 
2
 
 pups at birth on the C57BL/6 background (20). Vari-
ations in the time of fertilization do lead to differences in the size
and developmental stage of harvested fetuses. However, we have
not noted any variation between experiments in the ability of a
fixed dose of 10
 
6
 
 fetal liver cells to rescue lethally irradiated host
animals.
 
Genotyping at Sod2 Locus Using PCR.
 
DNA was extracted
from fetal liver cell suspensions using a DNA isolation kit accord-
ing to the manufacturer’s instructions (Gentra Systems). PCR
was performed using the following primer pairs: wild-type spe-
cific sequence 5
 
9
 
-AGG GCT CAG GTT TGT CCA GAA
AAT-3
 
9
 
 and common primer 5
 
9
 
-CGA GGG GCA TCT AGT
GGA GAA GT-3
 
9
 
; SOD mutation 5
 
9
 
-TTT GTC CTA CGC
ATC GGT AAT GAA-3
 
9
 
 and common primer as above. PCR
conditions were: 95
 
8
 
C for 2 min followed by 30 cycles of 95
 
8
 
C
for 30 s, 60
 
8
 
C for 30 s, 72
 
8
 
C for 1 min, with a final extension at
72
 
8
 
C of 4 min.
 
Host Animal Conditioning and Fetal Liver Transplantation.
 
C57BL/6 mice congenic at the Ly5 locus (B6.SJL-
 
Ptprc
 
a
 
Pep
 
3b
 
/
BoyJ[Ly5.1]) were obtained from the National Cancer Institute
and were used as recipients in order to allow for differentiation of
host (Ly5.1) versus donor (Ly5.2) hematopoietic cells. Ly5.1 host
animals (age 11–15 wk) were subjected to 10.50 cGy (1,050 rad)
of gamma irradiation divided into two equal doses 4 h apart on
the day of transplant. 10
 
6
 
 fetal liver cells, prepared as noted above,
were injected intravenously (either into tail vein or infraorbital si-
nus) into irradiated Ly5.1 congenic recipients. Animals were
maintained on chlorinated water for 21 d after irradiation. All ex-
periments were approved by the Animal Use Committee.
 
Analysis of Fetal Liver Cell Engraftment.
 
After recovery from
transplantation, mice were bled at 3–4 wk and every 4–8 wk
thereafter to assess the donor contribution to peripheral T cells, B
cells, granulocytes, and macrophages. Transplanted Ly5.1 mice
were bled from the ocular venus sinus, and 
 
z
 
250 
 
m
 
l of blood was
collected into 0.5 cc of PBS/EDTA (3 mg/ml EDTA). Samples
were then mixed with 0.5 cc of dextran T-500 in PBS (2% dex-
tran) and allowed to sediment for 30 min at 37
 
8
 
C. Leukocytes
were recovered in the supernatant and were mixed with one vol-
ume of a 1:4 dilution of saline/water to lyse remaining red cells.
After 5 min, one volume of 1.9% saline was added, and the sam-
ples were spun down to pellet leukocytes. Cells were resuspended
in FACS
 
®
 
 wash solution (PBS, 3% heat inactivated bovine serum,
0.02% sodium azide) with Fc block (BD PharMingen). After 15
min, the cells were mixed with an equal volume of biotinylated
anti–mouse CD45.2 (Ly 5.2) antibody (BD PharMingen). After
30 min, the cells were washed, spun down, and aliquoted into
mixtures containing streptavidin R-PE (Southern Biotechnology
Associates, Inc.) and either FITC-labeled CD90.2 for T cells,
FITC-labeled CD45RA for B cells, or a combination of FITC-
labeled CD11b and FITC-labeled Ly-6G for myeloid cells (all
from BD PharMingen). After 30 min, cells were washed and re-
suspended in FACS
 
®
 
 wash solution plus propidium iodide for
FACS
 
®
 
 analysis on a FACStar™ machine (Becton Dickinson). 
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Western Blot Analysis of MnSOD, CuZnSOD, and Porin Pro-
teins.
 
Polyclonal rabbit antisera specific for CuZnSOD and
MnSOD (StressGen Biotechnologies) were used to blot whole
cell lysate and red cell lysate obtained from fetal liver transplant
recipients. Anti-porin antibody was obtained from Calbiochem.
Bone marrow from transplanted animals was used as a source of
nucleated cells in order to obtain an estimate of the ratio be-
tween porin and CuZnSOD and porin and MnSOD. Second
stage horseradish peroxidase–conjugated anti–rabbit antibody
and anti–mouse antibody were obtained from Amersham Phar-
macia Biotech.
 
Protein Oxidation in Red Cells of Transplanted Animals.
 
Red
cell lysate proteins (20 
 
m
 
g protein/reaction) from 
 
Sod2
 
1
 
/
 
1
 
,
 
Sod2
 
1
 
/
 
2
 
, and 
 
Sod2
 
2
 
/
 
2
 
 transplant recipients were reacted with
2,4-dinitrophenylhydrazine to derivatize carbonyl groups formed
through protein oxidation using oxyblot reagents (Intergen).
Control samples were treated identically, except 2,4-dinitro-
pheylhydrazine was omitted. Proteins were then subjected to
SDS-PAGE followed by Western blot detection of derivatized
residues according to the oxyblot protocol. Samples were nor-
malized for protein concentration and verified by secondary
blotting for SOD1.
 
Therapeutic Trial of EUK-8 in Transplanted Mice.
 
EUK-8 was
provided by Eukarion. EUK-8 powder was resuspended in sterile
5% dextrose at a concentration of 3 mg/ml and passed through a
0.2-micron sterile filter. For the experiment detailed in Fig. 6,
mice were transplanted 13 wk before initiation of Euk-8 therapy.
Peripheral blood samples were obtained at 4 and 8 wk after trans-
plant to verify reconstitution with donor (Ly5.2)-derived cells.
Mice were weighed and bled at 13 wk to determine EUK-8 dos-
age and to obtain a baseline complete blood count (CBC). Ani-
mals received either 30 mg/kg EUK-8 3 d/wk, or vehicle alone
via intraperitoneal injection, on the same schedule for a total of 8
wk. Mice were bled again at 4 and 8 wk for hematocrit, reticulo-
cyte count, and blood smear.
 
Measurement of RBC Half-life.
 
Animals were transplanted 4
mo before RBC labeling to ensure that no residual pretransplant
host red cells remained. Animals were bled 5 wk before RBC la-
beling and demonstrated 100% donor-derived B cells, 
 
z
 
85% do-
nor-derived T cells, and 
 
z
 
90% donor-derived myeloid cells.
 
N
 
-hydroxysuccinimide (NHS)-biotin (E-Z link; Pierce Chemi-
cal Co.) was suspended in sterile saline at a concentration of 4
mg/ml and injected intravenously into fetal liver transplant recip-
ients. Animals received a total dose of 30–40 mg/kg of body
weight in a volume of 200–250 ml. Animals were first bled z36 h
after injection, and then at 2–3-d intervals for the first 2 wk, fol-
lowed by 3–4-d intervals for the third and fourth weeks, then
weekly twice more. Care was taken to obtain the smallest
amount of blood possible, typically 5–10 ml with each blood
sampling. Labeled cells were analyzed by FACS® after staining
with streptavidin R-PE. The exponential curve showing both
age-dependent and -independent processes was fitted to the
equation:  A(t) 5 A0[1 2 (t/T)]e2kt (reference 21), where A(t) is
the fraction of labeled RBCs present at time (t), A0 is the initial
fraction of labeled RBCs at t 5 0, T is the time of senescent
death of RBC (extinction time), and k is the fraction of cells
which are removed independent of RBC age (hemolysis). In this
experiment, k 5 0 for Sod21/1 and Sod21/2 cells, and k 5 0.04
for Sod22/2 cells.
Membrane Deformability. Cellular deformability was moni-
tored by ektacytometry using a Technicon ektacytometer (Bayer
Diagnostics). The osmotic deformability curve was recorded as
described previously (22).
Results
Reconstitution and Engraftment Kinetics. Fetal liver cells
for transplantation were generated by crossing Sod21/2 ani-
mals. Initial transplants compared the reconstituting ability
of fetal liver cells of each genotype (wild-type, heterozy-
gous, or knockout at the Sod2 locus). Survival was 100% in
all groups. Regardless of the genotype of the donor cells,
.95% of peripheral blood B cells and .83% of peripheral
blood myeloid cells were derived from the donor fetal liver
cells at 3 wk after transplant. T cell engraftment was more
gradual, with donor T cells first appearing in peripheral
blood 3–4 wk after transplant. Donor-derived T cells con-
tinued to increase and reached 80–90% of all peripheral
blood T cells by 3 mo after transplant. Throughout this ex-
periment, B cell and myeloid engraftment has remained
.90% and T cell engraftment .80% up to 1 yr after trans-
plant, with no evidence of a difference in kinetics or dura-
tion of engraftment related to donor genotype. Thus,
Sod22/2 hematopoietic stem cells are capable of giving rise
to normal numbers of T cells, B cells, and myeloid cells,
and can maintain this cellular output for up to 1 yr with no
evidence of a decline in graft function.
Reconstitution of Spleen, Bone Marrow, and Thymus. He-
matolymphoid tissues from transplanted animals were har-
vested to investigate in more detail engraftment among re-
cipients of Sod22/2,  Sod21/2, and Sod21/1 fetal liver.
Recipients of Sod22/2 cells had larger spleens than animals
receiving wild-type or heterozygous cells (4.2 3 108 vs.
2.3 3 108 cells/spleen; P 5 0.02). There was no enlarge-
ment of the thymus, lymph nodes, or Peyer’s patches com-
pared with control transplanted animals. Fig. 1 A shows flow
cytometric profiles of representative spleens from trans-
planted animals in which cells are simultaneously stained for
the donor-specific marker CD45.2 (Ly5.2) and for one of the
following lineage markers: Ly6G and CD11b for myeloid
cells, CD45RA for B cells, and CD90.2 for T cells. Spleens
from animals receiving Sod22/2 cells had a large population
of cells which did not stain for markers of B cells, T cells,
granulocytes, or macrophages, but which did stain for the
erythroid marker Ter119 (Fig. 1 B). These data demon-
strated effective reconstitution in all lineages (as expected
from the peripheral blood analysis) and revealed a greatly
expanded population of erythroid precursors in the spleens
of animals transplanted with Sod22/2 fetal liver cells. This
population represented 25–40% of the nucleated cells
present in spleens from Sod22/2 fetal liver recipients, com-
pared with 1–5% of nucleated spleen cells from Sod21/1 fe-
tal liver recipients. Splenic red cell precursors (Ter1191)
were stained with CD45.2 (Ly5.2 or donor antigen) or
CD45.1 (Ly5.1 or host antigen) to demonstrate that ery-
throid cells were also donor derived (Fig. 1 C). Analysis of
the bone marrow revealed additional evidence for in-
creased erythropoiesis in animals which received Sod22/2
cells, with the Ter119 population representing 40–50% of
nucleated marrow cells versus 20–30% of marrow cells in
recipients of Sod21/1 or Sod21/2 fetal liver cells (Fig. 1 B).
Total marrow cell number in recipients of Sod22/2 fetal928 Defective Erythropoiesis from Sod2 Knockout Fetal Liver Stem Cells
liver was slightly increased compared with recipients of
Sod21/1 fetal liver (range 1.0–1.25 times Sod21/1 cell
number). Analysis of the thymus from reconstituted ani-
mals revealed no differences in cell number or CD41 ver-
sus CD81 profile, suggesting that lack of SOD2 does not
significantly affect these measures of T cell reconstitution.
Sod22/2 Fetal Liver Recipients Are Anemic. Analysis of
peripheral blood and hematolymphoid tissues revealed nor-
mal lymphopoiesis and myelopoiesis, but suggested ab-
normalities restricted to the erythroid lineage. This was
substantiated by comparison of CBCs from transplant re-
cipients (obtained 3 mo after transplant) that showed ani-
mals reconstituted with Sod22/2 fetal liver cells were ane-
mic and had elevated circulating reticulocytes (P , 0.001).
In addition to hematocrit, several parameters were abnor-
mal in erythrocytes derived from Sod22/2 fetal liver (Table
I). Mature red cells in Sod22/2 recipients were smaller and
possessed less hemoglobin than those in control trans-
planted animals. Morphologic examination of peripheral
blood smears (Fig. 2, Wright-Giemsa stain) suggested a
hemolytic process affecting Sod22/2 red cells. There was a
marked reticulocytosis in Sod22/2 peripheral blood, and
variability in RBC size and shape. In addition, Sod22/2 red
cells had a high frequency of basophilic intracellular inclu-
sions that were absent from Sod21/1 cells, and which did
not appear to be Howell-Jolly bodies. Specific staining for
Heinz bodies revealed that Sod22/2–derived cells possess
more of these inclusions, thought to represent accumula-
tion of oxidized proteins within erythrocytes (data not
shown). White blood cell count, differential (not shown),
and platelet counts were not statistically different among
recipients of Sod21/1, Sod22/2, or Sod21/2 fetal liver cells.
We did not find consistent morphologic changes in leuko-
cytes or platelets between Sod22/2 and Sod21/1 smears.
Together, the examination of peripheral blood from
Sod22/2 fetal liver recipients demonstrated an anemia with
evidence of an ongoing hemolytic process.
Red Cell Half-life Is Decreased for Cells That Lack SOD2.
The anemia observed in Sod22/2 fetal liver recipients could
be due to increased red cell destruction (hemolysis) or de-
fective red cell maturation (ineffective erythropoiesis) or a
combination of both processes. To measure more directly
Figure 1. FACS® analysis of hemato-
lymphoid tissues from Sod22/2 and Sod21/1
fetal liver recipients. (A) Splenocytes from
transplanted animals were costained with
antibodies against the donor-derived
CD45.2 antigen and markers for myeloid
cells (CD11b and Ly-6G), B cells
(CD45RA), or T cells (CD90.2). Sod22/2
fetal liver recipients have a large population
of splenocytes that stain weakly for CD45.2
but do not express myeloid or lymphoid
markers. (B) Splenocytes and bone marrow
cells from recipients of Sod21/1 or Sod22/2
fetal liver cells were costained with CD45.2
and the erythroid marker Ter119. The population shown in Sod22/2 samples in panel A represents abundant erythroid precursors (23.4% of sample),
which are nearly absent from Sod21/1 samples (1.7%). Analysis of bone marrow with the same markers reveals that Sod22/2 recipients have increased
erythroid progenitors in this compartment as well. (C) Erythroid lineage cells (Ter1191) from the spleen of a Sod22/2 fetal liver recipient were co-
stained with either FITC–anti-Ly5.1 (host) or FITC–anti-Ly5.2 (donor) to demonstrate that erythroid precursor cells are also donor derived.929 Friedman et al.
whether the observed anemia was due to decreased pro-
duction of mature RBCs or increased destruction of RBCs
in the circulation, we measured RBC survival in trans-
planted animals, using direct in vivo biotin labeling (23).
RBC survival in Sod22/2 and control fetal liver recipients
was followed for 41 d in a random RBC labeling experi-
ment. The survival curves plotted in Fig. 3 show that RBC
removal was nearly linear for Sod21/1 and Sod21/2 fetal
liver recipients with a disappearance rate of 2.6% RBCs per
day and with an extinction time of z40 d. In contrast, in
the Sod22/2 fetal liver recipients, an exponential removal of
RBCs was noted, indicating that one component of RBC
destruction was independent of RBC age. The time re-
quired for loss of 50% of labeled Sod21/1 and Sod21/2
RBCs is 20 d, whereas the time required for loss of 50% of
labeled Sod22/2 RBCs is 10 d.
Red cell membrane flexibility is required for RBC
function, and alterations in membrane characteristics can
affect cell survival (24). Therefore, we determined the os-
motic deformability profile of RBCs from fetal liver recip-
ients. The combined curves of three Sod21/1 fetal liver re-
cipient and four Sod22/2 fetal liver recipient mice are
shown (Fig. 4). A shift in the curve for Sod22/2 versus
Sod21/1 RBCs is apparent, with the Sod22/2 cells showing
reduced deformability under isotonic conditions. In addi-
tion to a smaller mean corpuscular volume (MCV), this
shift may be due to a change in the mechanical properties
of the membrane as indicated by the hypertonic arm of the
curve, suggesting an overall increase in membrane stiffness.
Altered membrane deformability and decreased red cell
survival are both characteristics of the anemia that arises in
animals transplanted with Sod22/2 fetal liver stem cells.
This raises the interesting question of how deficiency in a
mitochondrial enzyme can shorten the half-life of a cell
that does not possess mitochondria.
SOD2 Protein Expression and Mitochondrial Distribution in
Bone Marrow Cells and Erythrocytes of Transplanted Ani-
mals. To address the role of SOD2 protein deficiency as a
cause of anemia, we determined the distribution of SOD2
and mitochondria in RBCs and marrow cells from trans-
planted animals (Fig. 5). We were unable to detect SOD2
Table I. CBC Comparison between Transplanted Animals
Sod21/1 Sod22/2 Sod21/2
Percent
hematocrit 48.1 6 0.6 31.8 6 1.6* 48.1 6 1.2
Percent
reticulocyte 2.8 6 0.2 16 6 2.8* 2.6 6 0.4
Mean corpuscular
volume (fl) 50.1 6 0.3 46.7 6 1.0* 48.1 6 1.3**
Red cell count
(3106) 9.6 6 0.2 6.8 6 0.3* 9.8 6 0.3
White cell count
(3103) 12.3 6 1.7 12 6 2.7 9.0 6 2.6
Platelet count
(3103) 1,075 6 139 1,262 6 137 1,062 6 103
Mean corpuscular
hemoglobin (pg) 14.9 6 0.1 13.8 6 0.4* 14.5 6 0.3
Red cell
distribution width 13.2 6 0.2 21.8 6 0.9* 13.2 6 0.3
CBC comparisons of Sod21/1,  Sod21/2, and Sod22/2 fetal liver
recipients. CBC was obtained 13 wk after fetal liver transplantation, and
5 wk after the most recent blood sampling for peripheral blood
reconstitution assessment. For all parameters tested except MCV, there
was no significant difference between Sod21/1 and Sod21/2 fetal liver
recipients.  Sod22/2 fetal liver recipients differ from Sod21/1 in
hematocrit, reticulocyte count, MCV, mean corpuscular hemoglobin,
and red cell distribution width.
*P , 0.001 compared with Sod21/1 sample.
**P , 0.01 compared with Sod21/1 sample.
Figure 2. Wright-Giemsa stain of peripheral blood smears from transplanted animals. Morphologic comparison of peripheral blood demonstrates
marked reticulocytosis and abnormal red cells in Sod22/2 fetal liver recipients. Many Sod22/2 RBCs have multiple prominent basophilic inclusions.
There are many hypochromic cells, as well as variations in cell size and cell shape. Occasional Howell-Jolley bodies are seen in both the Sod21/1 and
Sod22/2 red cells.930 Defective Erythropoiesis from Sod2 Knockout Fetal Liver Stem Cells
in RBC protein from Sod21/1 fetal liver recipients except
after prolonged exposure (data not shown), demonstrating
that there is very little SOD2 present in RBCs. SOD1,
which is known to be abundant in RBCs, was highly and
equally expressed in all samples. Examination of nucleated
cells revealed that SOD2 was abundant in Sod21/1 recon-
stituted bone marrow. A residual amount of SOD2 was de-
tected in the marrow of Sod22/2 fetal liver recipients, likely
derived from radio-resistant host stromal elements or a
small fraction of residual host hematopoietic cells. An inter-
mediate level of SOD2 was detected in the protein fraction
from the marrow of Sod21/2 reconstituted animals. Thus,
the expression of SOD2 in bone marrow cells of trans-
planted animals was reflective of the number of wild-type
copies of Sod2 in the transplanted cells and suggests that
nearly all marrow cells are donor derived.
The distribution of mitochondria in bone marrow and
RBC samples was tracked through detection of the mito-
chondrial voltage-dependent anion channel (porin 31HL;
reference 25). Porin was not seen in Sod21/1 or Sod21/2
RBCs. Conversely, porin was detected in Sod22/2 RBCs.
Analysis of bone marrow cell proteins for porin expression
shows slightly more porin in Sod22/2 compared with con-
trol fetal liver recipients. This finding suggests that SOD2-
deficient cells have increased numbers of mitochondria. Al-
ternatively, the increased porin levels in bone marrow may
reflect the increased erythroid precursor frequency we ob-
serve in Sod22/2 fetal liver recipients. In peripheral blood,
both the high reticulocyte count and increased numbers of
mitochondria per cell may contribute to the porin band de-
tected in Sod22/2–derived RBCs.
Sod22/2 Red Cells Possess More Oxidized Protein. Defi-
ciency of SOD2 has been shown to lead to both structural
and functional damage to mitochondria. We reasoned that
lack of SOD2 either during erythroid development or in
mature RBCs might be accompanied by increased protein
oxidation. We used an indirect assay for protein oxidation
that measures the amount of protein carbonyl groups
formed through the oxidation of amino acid side chains
(26). There was a slight increase in protein oxidation of
Sod21/2 red cells compared with Sod21/1 red cells, which
may be indicative of increased oxidative damage, although
this damage is not sufficient to cause a decrease in survival
of Sod21/2 RBCs (Fig. 3). In contrast, RBC proteins from
Sod22/2 recipients demonstrated dramatically higher levels
Figure 3. Red cell survival curve. In vivo biotin labeling was used to
follow red cell survival kinetics over a 6-wk period. Small samples (5 ml)
of peripheral blood were collected and stained using streptavidin-PE, fol-
lowed by FACS® analysis, to determine the fraction of labeled RBCs re-
maining. Sod21/1 and Sod21/2 RBCs are lost in a linear fashion (2.6% per
day) with an extinction time of z40 d. Sod22/2 cells show a similar ex-
tinction time, but their removal curve has an exponential component.
Figure 4. Red cell membrane osmotic deformability curve. Osmotic
deformability was determined by ektacytometry. The combined curves of
red cells from three Sod21/1 and four Sod22/2 fetal liver transplant recip-
ients are shown. Sod22/2 cells have reduced deformability compared with
controls.
Figure 5. Western blot for expression of SOD1, SOD2, and porin in
RBCs and bone marrow. 50 mg of total protein lysate from RBCs or
bone marrow cells of transplanted animals was separated on a 12% SDS
gel and blotted for protein expression. Red cell lysates contain abundant
SOD1, but do not contain detectable amounts of SOD2. The mitochon-
drial protein porin is present in bone marrow cells, and can be detected in
the RBC lysate of Sod22/2 transplant recipients. In a lighter exposure (*)
of bone marrow–derived protein, porin is also more abundant in the sam-
ple from Sod22/2 transplant recipients. SOD2 can be detected in the bone
marrow lysates, and with a lighter exposure (**) expression levels can be
correlated with the genotype of transplanted cells: Sod21/1 lysates express
the most, Sod21/2 lysates express less, and Sod22/2 lysates have ,5% the
level of SOD2 protein seen in Sod21/1 samples. Results shown for porin
and SOD2 expression are representative of four separate determinations.931 Friedman et al.
of oxidized protein compared with Sod21/2 or Sod21/1 fe-
tal liver recipients (Fig. 6), supporting the hypothesis that
accelerated RBC destruction in these animals is due to in-
creased protein oxidation.
Partial Correction of Anemia Using a Synthetic SOD/Cata-
lase Mimetic. We reasoned that if protein oxidation is cen-
tral to the pathogenesis of anemia in recipients of Sod22/2
fetal liver cells, treatment with antioxidant compounds
should ameliorate this condition. Indeed, previous work
demonstrates that the antioxidant compound MnTBAP,
which has SOD mimetic properties, can partially rescue the
phenotype of Sod22/2 mice (14). EUK-8, a synthetic SOD
mimetic that also possesses catalase activity, was tested in
our transplant model because prior studies had demon-
strated the efficacy of this compound in suppression of
ROS-mediated damage in vivo (27, 28) and in vitro (29,
30). Transplanted animals received Euk-8 or vehicle alone
by intraperitoneal injection three times/week for 2 mo.
Pretreatment hematocrit and reticulocyte counts were
compared with samples obtained after 4 and 8 wk of treat-
ment with EUK-8. Treatment had no effect on the hemat-
ocrit or reticulocyte count in recipients of Sod21/1 or
Sod21/2 fetal liver cells. After 4 wk of therapy, EUK-8–
treated compared with sham-treated Sod22/2 fetal liver re-
cipients had an increase in their hematocrit from 30.7 to
37.8% (P 5 0.01). This increase was maintained after 8 wk
of therapy (30.7 vs. 36.7%; P , 0.001), and was accompa-
nied by a corresponding decrease in the reticulocyte count
from 14% pretreatment to 8% (P value not significant) after
2 mo of therapy (Fig. 7). These results demonstrate that en-
hanced protection from oxidative stress using a combined
SOD/catalase mimetic can significantly ameliorate the ane-
mia observed in Sod22/2 fetal liver recipients.
Discussion
Sod22/2 Fetal Liver Stem Cells Have Full Reconstituting
Ability. We studied the effect of chronic intracellular ox-
idative stress on immune/hematopoietic cells that lack
SOD2, the enzyme responsible for detoxifying ROS gen-
erated during mitochondrial respiration. In a fetal liver
transplant model, we found no obvious differences in ra-
dio protection or in long-term reconstituting ability of
Sod22/2 stem cells compared with Sod21/1 or Sod21/2
cells. Further, 1 yr after transplant, there was no indication
of bone marrow failure related to the lack of SOD2. To
provide a more definitive answer as to whether lack of
SOD2 can affect the proliferative potential of murine he-
matopoietic stem cells, with increasing age and/or under
conditions of greater proliferative stress, the use of com-
petitive repopulation assays and secondary transplantation
are required.
Although we did not use hemoglobin electrophoretic
variants or isozyme markers to quantitate donor-derived
erythrocytes in our transplanted animals, several points from
our data suggest that erythroid replacement was nearly
complete. First, in normal hematopoietic cell reconstitu-
tion, myeloid and erythroid differentiation are closely con-
nected, and thus it is likely that the near 100% donor-
derived myeloid engraftment we observed is accompanied
by a near 100% donor-derived erythroid engraftment (31).
Next, when we stained bone marrow and spleen cells for
the combination of CD45 and the erythroid-specific
marker Ter119, we found Ter1191 nucleated cells that
stain weakly (1/dim) for the donor CD45.2 marker (Fig. 1,
B and C). However, the analogous (host-derived) Ter1191,
CD45.11/dim population was absent, suggesting that ery-
throid precursors were of donor origin (Fig. 1 C). Finally,
when we analyzed protein derived from bone marrow of
transplanted animals for levels of SOD2, only a minimal
amount of SOD2 could be detected in recipients of Sod22/2
fetal liver cells compared with recipients of Sod21/1 and
Sod21/2 fetal liver (Fig. 5). Therefore, even in the absence
of a donor-specific marker for mature erythrocytes, our data
strongly suggest that virtually all red cells are donor derived.
Figure 6. Comparison of oxi-
dized protein among trans-
planted RBCs. 20 mg of protein
from RBC lysates of Sod22/2,
Sod21/1, and Sod21/2 fetal liver
transplant recipients was reacted
with 2,4-dinitrophenylhydra-
zine to derivatize (D) protein
carbonyl groups, which were
then detected using an anti-
DNP antibody. 20 mg of each
protein sample was incubated in
reaction buffer alone to serve as
a control (C). RBC proteins
from Sod22/2 recipients have
higher levels of oxidized protein
residues. Secondary blotting us-
ing antisera against SOD1 was
performed to verify equivalent
protein loading (bottom panel).
Figure 7. Partial correction of anemia using Euk-8, a synthetic SOD/
catalase. Transplanted animals were divided into two groups that received
either Euk-8 at a dose of 30 mg/kg 3 d/wk, or sham injections on the same
schedule. Hematocrit (Hct.) and reticulocyte (Retic.) counts were deter-
mined after 8 wk of treatment. There was no effect of drug treatment on
the hematocrit of animals that received Sod21/1 or Sod21/2 fetal liver cells.
Recipients of Sod22/2 cells showed a significant increase in hematocrit in
response to Euk-8 treatment after 8 wk (*P , 0.001) of therapy, and a cor-
responding decrease in reticulocyte count (P value not significant).932 Defective Erythropoiesis from Sod2 Knockout Fetal Liver Stem Cells
Sod22/2 Stem Cells Produce Defective Erythrocytes.
Sod22/2 fetal liver recipients were found to be persistently
anemic, with erythroid hyperplasia in both the spleen and
marrow as measured by the increased percentage of
Ter119-positive cells. Anemia was noted as a characteristic
of knockout mice of both the Sod2tm1BCM strain (13) and
the Sod2tm1Cje strain used in this study. In analysis of
the anemia, it was found that the bone marrow of
Sod2tm1BCM2/2 animals was hypocellular compared with
control littermates. Yet, in our transplant model, we found
marked erythroid hyperplasia in the bone marrow, with
normal or increased total cell numbers. This suggests that
the hypocellular marrow found in Sod2tm1BCM2/2 animals is
secondary to an environmental defect rather than a stem
cell defect. However, when considering the erythroid lin-
eage, defects are evident even when the metabolic environ-
ment of the host animal is normal. This clearly demon-
strates an intrinsic defect in Sod22/2 erythroid progenitors.
In addition, we show that whereas Sod22/2 progenitor cells
are capable of expansion in both the spleen and marrow in
response to anemia, they are only able to partially compen-
sate for loss of red cells. Splenic erythropoiesis is increased
in Sod22/2 fetal liver recipients, but the degree of erythroid
hyperplasia observed is less than that seen in other murine
anemia models with a similar hematocrit. This discordance
between the degree of anemia and the response may result
from intrinsic differences in the response of Sod22/2 stem
cells or erythroid progenitors to homeostatic control of he-
matocrit through erythropoietin and other growth factors.
Alternatively, the degree of erythroid hyperplasia possible
in our model system may be limited due to irradiation of
host tissues (specifically the spleen) before transplantation.
SOD2 deficiency anemia could be due to a defect incor-
porated into red cells during development that is unmasked
upon exposure to oxidative stress in the circulation. The
partial pressure of oxygen in the marrow (and spleen) is es-
timated to be quite low (24–40 mm Hg; reference 32), and
therefore these environments may be relatively permissive
for SOD2-deficient cells to develop with minimal oxida-
tive damage. We speculate that most of the damage to
RBCs occurs in the (arterial) circulation where the partial
pressure of oxygen is the highest. In support of this conjec-
ture, we see only a modest increase in total oxidized pro-
tein from bone marrow cells of Sod22/2 reconstituted ani-
mals, whereas there is a dramatic increase in oxidized
protein in circulating RBCs of the same animals. We have
also noted that Sod22/2 marrow and peripheral blood cells
have elevated levels of the mitochondrial protein porin, in-
dicating that these cells have a greater number or mass of
mitochondria than found in Sod21/1 or Sod21/2 cells. The
accumulation of abnormal mitochondria in Sod22/2 red
cell precursors and their persistence in circulating reticulo-
cytes may be both necessary and sufficient to explain the
observed increase in oxidative damage to Sod22/2 red cells.
In such a model, the mitochondria serve as the locus for
ROS production, and those cells maintaining the most mi-
tochondria for the longest period of time in the circulation
sustain the most damage. Cells that successfully extrude or
degrade their mitochondria rapidly would be relatively
spared. This model is in accord with our observed red cell
survival data, as some Sod22/2 cells are removed prema-
turely whereas other cells have a normal extinction time
(Fig. 3). The magnitude of the premature removal effect is
most pronounced at the early time points, suggesting a lim-
ited window during which young RBCs may accumulate
“fatal” oxidative damage.
We have observed two consequences secondary to accu-
mulation of oxidized protein in SOD2-deficient cells: de-
creased RBC survival and altered RBC membrane defor-
mation. Decreased RBC survival and reduced membrane
deformability are common characteristics of a wide range
of hemolytic processes. However, protein oxidation, as
shown by the increased protein carbonyl content of
SOD2-deficient cells, may be a useful marker when applied
to the classification of other anemias, and may help to de-
fine those conditions most likely to respond to antioxidant
therapy.
Characterization of anemia secondary to SOD2 defi-
ciency has the potential to further our understanding of,
and therapeutic approach to, a subset of human erythrocyte
disorders. Interestingly, there are morphologic similarities
between SOD2-deficient RBCs and red cells from patients
with SA, particularly the prominence of basophilic inclu-
sions within immature RBCs, and the increased frequency
of Heinz bodies. However, there are notable differences
between SOD2 deficiency in mice and human SA. In par-
ticular, the morphologic abnormalities in human SA in-
volve red cell precursors in the marrow, and patients with
SA do not have a prominent reticulocytosis. In our model
of SOD2 deficiency, we observe “siderocytes” in the pe-
ripheral blood, with very few sideroblasts evident in either
the marrow or the erythropoietically active spleen. Despite
these differences, the pathogenesis of anemia in both the
SOD2-deficient model and in human SA involves mito-
chondrial dysfunction.
Two types of congenital SA have been shown to involve
mitochondrial pathology. In Pearson marrow pancreas syn-
drome, large deletions are found in mitochondrial DNA
(19, 33). In X-linked sideroblastic anemia with cerebellar
ataxia, the human ABC7 transporter gene, which is in-
volved in the maturation of iron-sulfur cluster-containing
proteins, is mutated (18). There is also evidence that ac-
quired SA may be caused by de novo mutations in mito-
chondrial DNA, specifically in subunit I of cytochrome C
oxidase (34). Ultrastructural analysis of RBC precursors in
SA reveals deposition of iron within mitochondria (35).
Iron accumulation is proposed to occur in dysfunctional
mitochondria when Fe31 cannot be reduced to Fe21,
which is required for heme synthesis (36). A possible unify-
ing feature between these disorders and SOD2 deficiency is
an abnormality in mitochondrial iron homeostasis. Abnor-
mal iron homeostasis in Sod2-deficient cells is suggested by
the measurement of severely depressed enzymatic activity
of several iron-sulfur cluster-containing proteins in mito-
chondria from tissues of Sod22/2 mice (15). SA would then
be a common morphologic pattern seen as a consequence933 Friedman et al.
of the inability of dysfunctional mitochondria (representing
many different primary defects) to successfully incorporate
iron into heme.
Because of the unambiguous role of increased oxidative
stress as the etiologic agent of anemia due to loss of SOD2,
we performed a therapeutic trial using a synthetic SOD/
catalase mimetic compound. Euk-8 and related compounds
have advantages over traditional free radical scavengers such
as ascorbate, as they possess catalytic SOD and catalase ac-
tivities, and thus are able to degrade both superoxide anions
and peroxides without being consumed in the reactions (37,
38). In our system, we have seen a partial, though highly
significant correction of the anemia when using a single
dose, route, and frequency of administration of Euk-8. Be-
cause none of these parameters has been optimized, it is
likely that a more complete correction of the anemia will be
possible. If catalytic antioxidant compounds such as Euk-8
prove to be useful in the treatment of human conditions
like SA, they have the potential to reduce transfusion re-
quirements and the toxicity associated with iron overload-
ing, and would represent a welcome additional therapeutic.
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